Journal
JOURNAL OF CONTROLLED RELEASE
Volume 336, Issue -, Pages 549-571Publisher
ELSEVIER
DOI: 10.1016/j.jconrel.2021.07.003
Keywords
Glioblastoma multiforme; Temozolomide; Nanocarriers; BBB; Liposomes; Dendrimers; Quantum dots; Gene delivery
Ask authors/readers for more resources
GBM, a life-threatening IV grade glioma brain cancer, remains a challenge to treat due to the toxic nature and fast degradation of TMZ, along with lack of targeting ability increasing chances of systemic toxicities. Nano-enabled technology improves the efficiency of TMZ and reduces toxicity to healthy tissues.
Glioblastoma multiforme (GBM) is abnormal cell proliferation of glial cells. GBM is the grade IV glioma brain cancer which is life-threatening to many individuals affected by this cancer. The DNA alkylating agent Temo-zolomide (TMZ) has the distinctiveness of being FDA approved anticancer drug for the first line treatment for GBM. However, treatment of GBM still remains a challenge. This is attributed to TMZ's toxic nature, severe side effects, and fast degradation in vivo. In addition, the lack of targeting ability increases the chances of systemic toxicities. A nano enabled targeted delivery system not only improves the efficiency of TMZ by making it cross the blood brain barrier, have specificity to target, but also reduces toxicity to healthy tissues. Over the last decade the significant advances in the area of nanotechnology applied to medicine have developed many multifunctional therapeutics. In this context, the present review article comprehends the significant progress in the field of TMZ loaded nanocarriers showing promise for futuristic nanomedicine therapies in treating GBM.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available